Immunovant, Inc. annual earnings per share (EPS) for fiscal 2025 was $-2.73, a decrease of 45.2% from $-1.88 in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Diluted EPS | — | ($3M) | ($2M) | ($2M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Diluted EPS | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Revenue · Operating Income · Net Income · Free Cash Flow
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources